文献速递前列腺癌

多参数磁共振成像在前列腺癌主动监测中的作用:系统评价与诊断荟萃分析

Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-11-28

该系统评价与诊断荟萃分析纳入43项研究共6605例接受主动监测的前列腺癌患者,评估多参数磁共振成像(mpMRI)预测疾病再分类的效能。结果显示1.5T mpMRI敏感度0.60、阴性预测值0.75、HSROC 0.74;3.0T mpMRI敏感度0.81、阴性预测值0.78、HSROC 0.83。结论认为1.5T或3.0T mpMRI均是监测主动监测随访中疾病进展的有效工具,但疾病进展的mpMRI定义仍需进一步评估。

要点

  • 3.0T mpMRI预测再分类敏感度0.81、阴性预测值0.78、HSROC 0.83。
  • 1.5T mpMRI预测再分类敏感度0.60、阴性预测值0.75、HSROC 0.74。
  • mpMRI可作为主动监测随访中监测进展的有效工具。

核心结论

  • 现有证据表明1.5T或3.0T mpMRI均是主动监测随访中监测进展的有效工具,在检测前列腺癌再分类方面显示良好准确性。
  • 如何更好地定义mpMRI上的「疾病进展」仍需进一步评估。

研究设计与样本

  • 最终纳入43项研究,共6605例接受主动监测的前列腺癌患者。
  • 对3.0T mpMRI预测疾病再分类进行诊断荟萃分析。

主要发现

  • 各研究在主动监测随访中MRI的时机及主动监测方案纳入标准方面存在差异。
  • 所有研究总体偏倚风险低。
  • 1.5T mpMRI敏感度0.60、阴性预测值0.75、HSROC 0.74。
  • 3.0T mpMRI敏感度0.81、阴性预测值0.78、HSROC 0.83。

关键数值与推荐

  • 1.5T mpMRI预测疾病再分类:敏感度0.60,阴性预测值0.75,HSROC 0.74。
  • 3.0T mpMRI预测疾病再分类:敏感度0.81,阴性预测值0.78,HSROC 0.83。

临床怎么用

  • 在主动监测随访中可考虑使用1.5T或3.0T mpMRI监测疾病进展。
  • 解读mpMRI结果时需注意各研究随访时机和主动监测纳入标准存在差异。

局限性

  • 各研究MRI随访时机及主动监测方案纳入标准不一致。
  • mpMRI上「疾病进展」的定义尚未统一,需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of multiparametric magnetic resonance imaging (mpMRI) in the setting of patients under active surveillance (AS) is promising. In this systematic-review we aimed to analyse the role of mpMRI in patients under AS. METHODS: A comprehensive literature research for English-language original and review articles, recently published, was carried out using Medline, Scopus and Web of sciences databases until 30 October 2017. The following MeSH terms were used: 'active surveillance', 'prostate cancer', 'multiparametric magnetic resonance imaging'. A diagnostic meta-analysis was performed for 3.0 T mpMRI in predicting disease re-classification. RESULTS: In total, 226 studies were selected after research and after removal of duplicates. After analysis on inclusion criteria, 43 studies were identified as eligible for this systematic review with a total of 6,605 patients. The timing of MRI during follow-up of AS differed from all studies like criteria for inclusion in the AS protocol. Overall, there was a low risk of bias across all studies. The diagnostic meta-analysis for 1.5 tesla showed a sensitivity of 0.60, negative predictive value (NPV) of 0.75 and a hierarchical summary receiving operating curve (HSROC) of 0.74 while for 3.0 tesla mpMRI a sensitivity of 0.81, a NPV of 0.78 and a HSROC of 0.83. CONCLUSIONS: Overall, the available evidence suggests that both 1.5 or 3.0 Tesla mpMRI are a valid tool to monitor progression during AS follow-up, showing good accuracy capabilities in detecting PCa re-classification. However, the modality to better define what means 'disease progression' on mpMRI must be further evaluated.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Cantiello F, Russo GI, Kaufmann S, et al. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer Prostatic Dis. 2018. PMID: 30487646. doi:10.1038/s41391-018-0113-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。